Considering these new insights and the increase of CCR1 levels in serum following PD establishment, CCR1 might be a pathogenic marker and a useful target for innovative immunotherapeutic strategies in the perspective of dopaminergic neuron survival. Here, CCR1 is linked to Parkinson disease.